SK1892001A3 - Muscarinic agonists and antagonists, pharmaceutical composition them comprising and use thereof - Google Patents

Muscarinic agonists and antagonists, pharmaceutical composition them comprising and use thereof Download PDF

Info

Publication number: SK1892001A3
Authority: SK; Slovakia
Prior art keywords: alkyl; azatricyclo; independently; compound; halogen
Prior art date: 1998-08-18

Application number

SK189-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Gurmit Grewal

Anna Toy-Palmer

Xiong Cai

George Mark Latham

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-18

Filing date

1999-08-16

Publication date

2001-11-06

1999-08-16 Application filed by Ucb Sa filed Critical Ucb Sa

2001-11-06 Publication of SK1892001A3 publication Critical patent/SK1892001A3/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
239000000472 muscarinic agonist Substances 0.000 title description 9
239000003149 muscarinic antagonist Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 89
208000002193 Pain Diseases 0.000 claims abstract description 18
230000036407 pain Effects 0.000 claims abstract description 15
-1 -OH Inorganic materials 0.000 claims description 65
238000000034 method Methods 0.000 claims description 24
229910052736 halogen Inorganic materials 0.000 claims description 22
229920006395 saturated elastomer Polymers 0.000 claims description 22
150000002367 halogens Chemical class 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 20
125000004093 cyano group Chemical group *C#N 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 16
125000003118 aryl group Chemical group 0.000 claims description 15
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 12
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 12
125000005842 heteroatom Chemical group 0.000 claims description 12
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 12
229910052799 carbon Inorganic materials 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
125000000623 heterocyclic group Chemical group 0.000 claims description 11
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 10
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000004122 cyclic group Chemical group 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
239000000651 prodrug Substances 0.000 claims description 6
229940002612 prodrug Drugs 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
229910052757 nitrogen Inorganic materials 0.000 claims description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
150000002431 hydrogen Chemical group 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
230000006949 cholinergic function Effects 0.000 claims description 3
201000000980 schizophrenia Diseases 0.000 claims description 3
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
208000015114 central nervous system disease Diseases 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
125000003342 alkenyl group Chemical group 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
208000035475 disorder Diseases 0.000 claims 3
BVLWZZNUQSYJOG-UHFFFAOYSA-N BrC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 Chemical compound BrC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 BVLWZZNUQSYJOG-UHFFFAOYSA-N 0.000 claims 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
230000000202 analgesic effect Effects 0.000 claims 2
INDYXBQOPZTSTJ-UHFFFAOYSA-N 2-pyridin-3-yl-1-azatricyclo[3.3.1.13,7]decane Chemical compound C1C(C2)CC3CC1CN2C3C1=CC=CN=C1 INDYXBQOPZTSTJ-UHFFFAOYSA-N 0.000 claims 1
ADMGCHXOTILZAP-UHFFFAOYSA-N CC(C)OC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 Chemical compound CC(C)OC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 ADMGCHXOTILZAP-UHFFFAOYSA-N 0.000 claims 1
WTTLLKAMZRPQQS-UHFFFAOYSA-N CCOC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 Chemical compound CCOC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 WTTLLKAMZRPQQS-UHFFFAOYSA-N 0.000 claims 1
NRJLFPGRQMOVIQ-UHFFFAOYSA-N NC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 Chemical compound NC1=CN=CC(C2N3CC4CC(C3)CC2C4)=C1 NRJLFPGRQMOVIQ-UHFFFAOYSA-N 0.000 claims 1
VODCVOLSDCFBLD-UHFFFAOYSA-N OC1C(C2)CC3CC1CN2C3C1=CC=CN=C1 Chemical compound OC1C(C2)CC3CC1CN2C3C1=CC=CN=C1 VODCVOLSDCFBLD-UHFFFAOYSA-N 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
ACUZDYFTRHEKOS-UHFFFAOYSA-N decan-2-ol Chemical compound CCCCCCCCC(C)O ACUZDYFTRHEKOS-UHFFFAOYSA-N 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
125000005936 piperidyl group Chemical group 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
230000001624 sedative effect Effects 0.000 description 12
239000000243 solution Substances 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 10
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
230000003502 anti-nociceptive effect Effects 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
238000003756 stirring Methods 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
230000001713 cholinergic effect Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
HDJRNMVQLGESEX-UHFFFAOYSA-N 4-chlorothiadiazole Chemical compound ClC1=CSN=N1 HDJRNMVQLGESEX-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
150000001347 alkyl bromides Chemical class 0.000 description 4
230000036592 analgesia Effects 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000000064 cholinergic agonist Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
230000000926 neurological effect Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 3
FWWBBQGYQSXIPP-UHFFFAOYSA-N 1-azabicyclo[3.3.1]non-2-ene Chemical class C1C=CN2CCCC1C2 FWWBBQGYQSXIPP-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102000009660 Cholinergic Receptors Human genes 0.000 description 3
108010009685 Cholinergic Receptors Proteins 0.000 description 3
208000000094 Chronic Pain Diseases 0.000 description 3
241000283086 Equidae Species 0.000 description 3
102000007216 Muscarinic M4 Receptor Human genes 0.000 description 3
108010008414 Muscarinic M4 Receptor Proteins 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
208000020016 psychiatric disease Diseases 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000003826 tablet Substances 0.000 description 3
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
WZZPXVURFDJHGI-LLVKDONJSA-N 3-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-4-butylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1[C@H]1C(CC2)CCN2C1 WZZPXVURFDJHGI-LLVKDONJSA-N 0.000 description 2
125000005917 3-methylpentyl group Chemical group 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
XGZKYPXTXBKQTM-UHFFFAOYSA-N 42949-24-6 Chemical compound C1C(C2)CC3C(=O)C1CN2C3 XGZKYPXTXBKQTM-UHFFFAOYSA-N 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
102000017924 CHRM4 Human genes 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010039424 Salivary hypersecretion Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
101100107916 Xenopus laevis chrm4 gene Proteins 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000013543 active substance Substances 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000003551 muscarinic effect Effects 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
239000012053 oil suspension Substances 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000047 product Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
208000026451 salivation Diseases 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
BVOBEKTUNHUKRO-UHFFFAOYSA-N 1,2-dimethoxyethane;methanol Chemical compound OC.COCCOC BVOBEKTUNHUKRO-UHFFFAOYSA-N 0.000 description 1
MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
WENISBCJPGSITQ-UHFFFAOYSA-N 1-azatricyclo[3.3.1.13,7]decane Chemical class C1C(C2)CC3CC1CN2C3 WENISBCJPGSITQ-UHFFFAOYSA-N 0.000 description 1
MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
DKKVKJZXOBFLRY-UHFFFAOYSA-N 1-cyclopropylethanol Chemical compound CC(O)C1CC1 DKKVKJZXOBFLRY-UHFFFAOYSA-N 0.000 description 1
BBYWOYAFBUOUFP-JOCHJYFZSA-N 1-stearoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN BBYWOYAFBUOUFP-JOCHJYFZSA-N 0.000 description 1
PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QDEXFMQOYIUZRK-UHFFFAOYSA-N 4-(1-azabicyclo[2.2.2]octan-2-yl)thiadiazole Chemical class C1CN2CCC1CC2C1=CSN=N1 QDEXFMQOYIUZRK-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical compound C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001535291 Analges Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010069632 Bladder dysfunction Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
241000282412 Homo Species 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000008484 agonism Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003965 antinociceptive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
208000025307 bipolar depression Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
238000009960 carding Methods 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
NQYKOGPMIBDYAS-UHFFFAOYSA-N heptane;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCC NQYKOGPMIBDYAS-UHFFFAOYSA-N 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910001412 inorganic anion Inorganic materials 0.000 description 1
125000001905 inorganic group Chemical group 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000000463 material Substances 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002891 organic anions Chemical class 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000004866 oxadiazoles Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000004867 thiadiazoles Chemical class 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
239000010409 thin film Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

SK189-2001A 1998-08-18 1999-08-16 Muscarinic agonists and antagonists, pharmaceutical composition them comprising and use thereof SK1892001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9697798P	1998-08-18	1998-08-18
PCT/US1999/018570 WO2000011001A1 (en)	1998-08-18	1999-08-16	Muscarinic agonists and antagonists

Publications (1)

Publication Number	Publication Date
SK1892001A3 true SK1892001A3 (en)	2001-11-06

Family

ID=22260061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK189-2001A SK1892001A3 (en)	1998-08-18	1999-08-16	Muscarinic agonists and antagonists, pharmaceutical composition them comprising and use thereof

Country Status (30)

Country	Link
US (5)	US6093724A (de)
EP (1)	EP1112272B1 (de)
JP (1)	JP2002523416A (de)
KR (1)	KR20010072784A (de)
CN (1)	CN1312812A (de)
AR (1)	AR020199A1 (de)
AT (1)	ATE227724T1 (de)
AU (1)	AU750566B2 (de)
BG (1)	BG105256A (de)
BR (1)	BR9913072A (de)
CA (1)	CA2340946A1 (de)
CO (1)	CO5130018A1 (de)
DE (1)	DE69903961T2 (de)
EE (1)	EE200100096A (de)
ES (1)	ES2191455T3 (de)
HK (1)	HK1038918A1 (de)
HU (1)	HUP0103203A3 (de)
ID (1)	ID27544A (de)
IL (1)	IL141050A0 (de)
IS (1)	IS5827A (de)
NO (1)	NO20010804L (de)
NZ (1)	NZ509762A (de)
PE (1)	PE20000988A1 (de)
PL (1)	PL346247A1 (de)
RU (1)	RU2219179C2 (de)
SK (1)	SK1892001A3 (de)
TR (1)	TR200100462T2 (de)
WO (1)	WO2000011001A1 (de)
YU (1)	YU13301A (de)
ZA (1)	ZA200100978B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE200300189A (et) *	2000-10-19	2003-10-15	Pfizer Products Inc.	Sillatud piperasiinderivaadid
GB0117950D0 (en) *	2001-02-16	2001-09-19	Aventis Pharma Inc	Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
WO2002094827A1 (en) *	2001-05-23	2002-11-28	Neurosearch A/S	Fused tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20030064979A1 (en) *	2001-06-29	2003-04-03	Hansen Thomas Kruse	Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US6828328B1 (en) *	2002-03-01	2004-12-07	Ucb S.A.	Analgesic combination of muscarinic agonists
US7897766B2 (en)	2005-09-23	2011-03-01	Abbott Laboratories	Amino-aza-adamantane derivatives and methods of use
US8314119B2 (en) *	2006-11-06	2012-11-20	Abbvie Inc.	Azaadamantane derivatives and methods of use
US8076350B2 (en) *	2006-12-22	2011-12-13	Abbott Laboratories	Spirocyclic azaadamantane derivatives and methods of use
EP2139891B1 (de) *	2007-03-23	2012-09-05	Abbott Laboratories	4-substituierte azaadamantan-derivate und verfahren zu ihrer verwendung
ATE538122T1 (de) *	2007-03-23	2012-01-15	Abbott Lab	Acetamid- und carboxamid-derivate von azaadamantan sowie verfahren zu ihrer verwendung
AU2010262643B2 (en) *	2009-06-19	2015-02-19	Abbvie Inc.	Diazahomoadamantane derivatives and methods of use thereof
US10265311B2 (en)	2009-07-22	2019-04-23	PureTech Health LLC	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3061821T (pt)	2009-07-22	2019-09-05	PureTech Health LLC	Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en)	2010-04-23	2015-09-15	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
PE20131394A1 (es) *	2010-09-23	2014-01-11	Abbvie Inc	Monohidrato de derivados de aza-adamantano
US8759380B2 (en)	2011-04-22	2014-06-24	Cytokinetics, Inc.	Certain heterocycles, compositions thereof, and methods for their use
AU2018300980A1 (en)	2017-07-12	2020-01-02	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en)	2017-10-20	2024-07-01	Univ Vanderbilt	Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en)	2017-12-20	2019-06-27	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor m4
KR102408292B1 (ko)	2018-09-28	2022-06-10	카루나 세러퓨틱스 인코포레이티드	무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4739074A (en) *	1986-01-22	1988-04-19	Pennwalt Corporation	Adamantane spiro-pyrrolidine derivatives
IL88156A (en) *	1987-11-13	1997-02-18	Novo Nordisk As	Azacyclic compounds their preparation and pharmaceutical compositions containing them
US5527813A (en) *	1990-08-21	1996-06-18	Novo Nordisk A/S	Heterocyclic compounds and their preparation and use
WO1992011261A1 (en) *	1990-12-21	1992-07-09	Merck Sharp & Dohme Limited	4-azatricyclo[2.2.1.02,6]heptanes and pharmaceutical compositions
US5955470A (en) *	1991-06-11	1999-09-21	Merrell Pharmaceuticals, Inc.	Derivatives of amide analogs of certain methano bridged quinolizines
US5641791A (en) *	1991-08-13	1997-06-24	Novo Nordisk A.S	Heterocyclic compounds and their preparation and use
NZ321970A (en) *	1995-11-02	2000-02-28	Neurosearch As	Fused tropane-derivatives as neurotransmitter reuptake inhibitors
US5914338A (en) *	1996-04-02	1999-06-22	Novo Nordisk	Heterocyclic compounds and their preparation and use
US6057446A (en) *	1998-04-02	2000-05-02	Crooks; Peter Anthony	Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US5952339A (en) *	1998-04-02	1999-09-14	Bencherif; Merouane	Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US5986100A (en) *	1998-04-02	1999-11-16	Crooks; Peter Anthony	Pharmaceutical compositions and methods for use

1999
- 1999-08-16 US US09/375,149 patent/US6093724A/en not_active Expired - Fee Related
- 1999-08-16 CA CA002340946A patent/CA2340946A1/en not_active Abandoned
- 1999-08-16 IL IL14105099A patent/IL141050A0/xx unknown
- 1999-08-16 YU YU13301A patent/YU13301A/sh unknown
- 1999-08-16 WO PCT/US1999/018570 patent/WO2000011001A1/en not_active Ceased
- 1999-08-16 AU AU57758/99A patent/AU750566B2/en not_active Ceased
- 1999-08-16 EE EEP200100096A patent/EE200100096A/xx unknown
- 1999-08-16 EP EP99945064A patent/EP1112272B1/de not_active Expired - Lifetime
- 1999-08-16 HU HU0103203A patent/HUP0103203A3/hu unknown
- 1999-08-16 SK SK189-2001A patent/SK1892001A3/sk unknown
- 1999-08-16 JP JP2000566274A patent/JP2002523416A/ja active Pending
- 1999-08-16 PL PL99346247A patent/PL346247A1/xx not_active Application Discontinuation
- 1999-08-16 CN CN99809775A patent/CN1312812A/zh active Pending
- 1999-08-16 ID IDW20010377A patent/ID27544A/id unknown
- 1999-08-16 DE DE69903961T patent/DE69903961T2/de not_active Expired - Fee Related
- 1999-08-16 RU RU2001107139/04A patent/RU2219179C2/ru not_active IP Right Cessation
- 1999-08-16 AT AT99945064T patent/ATE227724T1/de not_active IP Right Cessation
- 1999-08-16 BR BR9913072-6A patent/BR9913072A/pt not_active IP Right Cessation
- 1999-08-16 NZ NZ509762A patent/NZ509762A/xx unknown
- 1999-08-16 TR TR2001/00462T patent/TR200100462T2/xx unknown
- 1999-08-16 HK HK02100409.3A patent/HK1038918A1/zh unknown
- 1999-08-16 KR KR1020017002128A patent/KR20010072784A/ko not_active Withdrawn
- 1999-08-16 ES ES99945064T patent/ES2191455T3/es not_active Expired - Lifetime
- 1999-08-17 AR ARP990104100A patent/AR020199A1/es unknown
- 1999-08-18 CO CO99052330A patent/CO5130018A1/es unknown
- 1999-08-18 PE PE1999000838A patent/PE20000988A1/es not_active Application Discontinuation
2000
- 2000-05-09 US US09/567,785 patent/US6251916B1/en not_active Expired - Fee Related
- 2000-10-17 US US09/690,494 patent/US6323194B1/en not_active Expired - Fee Related
2001
- 2001-01-26 IS IS5827A patent/IS5827A/is unknown
- 2001-02-05 ZA ZA200100978A patent/ZA200100978B/xx unknown
- 2001-02-14 BG BG105256A patent/BG105256A/xx unknown
- 2001-02-16 NO NO20010804A patent/NO20010804L/no not_active Application Discontinuation
- 2001-10-05 US US09/972,415 patent/US6423842B1/en not_active Expired - Fee Related
2002
- 2002-03-27 US US10/108,046 patent/US6555550B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL346247A1 (en)	2002-01-28
US6423842B1 (en)	2002-07-23
US6323194B1 (en)	2001-11-27
US6093724A (en)	2000-07-25
IS5827A (is)	2001-01-26
ID27544A (id)	2001-04-12
KR20010072784A (ko)	2001-07-31
IL141050A0 (en)	2002-02-10
NO20010804L (no)	2001-04-11
AU750566B2 (en)	2002-07-25
ATE227724T1 (de)	2002-11-15
ZA200100978B (en)	2002-02-05
US20020045617A1 (en)	2002-04-18
HUP0103203A2 (hu)	2002-01-28
EP1112272A1 (de)	2001-07-04
US6555550B1 (en)	2003-04-29
RU2219179C2 (ru)	2003-12-20
US6251916B1 (en)	2001-06-26
NO20010804D0 (no)	2001-02-16
CO5130018A1 (es)	2002-02-27
DE69903961D1 (de)	2002-12-19
HK1038918A1 (zh)	2002-04-04
YU13301A (sh)	2005-06-10
NZ509762A (en)	2002-12-20
EP1112272B1 (de)	2002-11-13
BR9913072A (pt)	2001-05-15
AR020199A1 (es)	2002-05-02
PE20000988A1 (es)	2000-09-30
WO2000011001A1 (en)	2000-03-02
JP2002523416A (ja)	2002-07-30
TR200100462T2 (tr)	2001-09-21
CA2340946A1 (en)	2000-03-02
DE69903961T2 (de)	2003-07-03
CN1312812A (zh)	2001-09-12
EE200100096A (et)	2002-06-17
HUP0103203A3 (en)	2002-10-28
AU5775899A (en)	2000-03-14
BG105256A (en)	2001-11-30
ES2191455T3 (es)	2003-09-01

Publication	Publication Date	Title
SK1892001A3 (en)	2001-11-06	Muscarinic agonists and antagonists, pharmaceutical composition them comprising and use thereof
AU775426B2 (en)	2004-07-29	New compounds
DE3878833T2 (de)	1993-06-09	Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
KR101052706B1 (ko)	2011-08-01	스피로인돌리논 유도체
JP7781774B2 (ja)	2025-12-08	Ｅｎｐｐ１のイミノスルファノン阻害剤
RU2549551C2 (ru)	2015-04-27	Производные диазагомоадамантана и способы их применения
US6890936B2 (en)	2005-05-10	Muscarinic antagonists
HUT77938A (hu)	1998-11-30	7-Azabiciklo[2,2,1]-heptán- és -heptén-származékok és kolinerg receptor ligandumként történő alkalmazásuk
JP2008525524A (ja)	2008-07-17	アリールスルホンアミドモジュレーター
US12331022B2 (en)	2025-06-17	Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
WO2008100620A2 (en)	2008-08-21	Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
KR20060128955A (ko)	2006-12-14	Ｍｃｈ 조절 효과를 갖는 치환된 ｎ-사이클로헥실이미다졸리논
AU2005214319A1 (en)	2005-09-01	Amino heterocyclic modulators of chemokine receptor activity
CA1321996C (en)	1993-09-07	Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
HUT74380A (en)	1996-12-30	7-azabicyclo-[2.2.1]-heptane and -heptene derivatives pharmaceutical compositions containing them, and process for producing former compounds
WO2004017966A1 (en)	2004-03-04	Five-membered heterocyclic compounds in the treatment of chronic and acute pain
EP1558610B1 (de)	2008-02-27	Substituierte aminochinuclidin verbindungen und deren verwendung als delta-opioid rezeptor liganden
DE10229762A1 (de)	2004-01-22	Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
CZ2001585A3 (cs)	2001-07-11	Nové azacyklické sloučeniny, farmaceutický prostředek s jejich obsahem a jejich použití
MXPA01001457A (en)	2001-12-13	Muscarinic agonists and antagonists
WO2018045907A1 (zh)	2018-03-15	一种新型2-酰氨基噻唑衍生物及其制备方法与用途
WO2025080609A1 (en)	2025-04-17	Isotryptamine tetracycles for treating brain disorders
HK40087766A (zh)	2023-09-15	包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂
HK40047619B (zh)	2024-11-22	四元环类衍生物调节剂、其制备方法和应用
HK1181752A (en)	2013-11-15	Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof